Operator
Greetings, and welcome to Global Blood Therapeutics conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn this conference over to Mr. Steven Immergut.
Please go ahead, sir. You may begin.
Steven Immergut
Senior Vice President, Head of Corporate Communications, and Investor Relations
Thank you, and welcome to GBT s conference call to discuss the company s financial results for the fourth-quarter and full-year 2020 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide a high-level update on our progress in the fourth quarter and over the full-year 2020; jeff Farrow, our chief financial officer, who will provide an overview of our financial results; and David Johnson, or DJ, our chief commercial officer, who will give an update on the Oxbryta launch.
Regeneron Pharmaceuticals Inc s quarterly profit surged past estimates on Friday, benefiting from a recovery in demand for its flagship eye drug and a jump in sales of its eczema drug, sending the drugmaker s shares up 3% before the bell. However, Regeneron recorded tepid sales from its dual antibody cocktail, REGEN-COV, which won U.S. emergency use authorization in November for non-hospitalized Covid-19 patients at high risk of becoming severely ill. Regeneron and rival Eli Lilly s antibody therapies have so far seen lackluster demand as patients need to be isolated for administering the drug through one-time intravenous infusion, which adds to the challenges faced by hospitals that are already teeming with cases of coronavirus infection.
By Deena Beasley (Reuters) - Eli Lilly and Co said on Monday a small trial of its experimental Alzheimer's drug found that it slowed by about a third .
Eli Lilly and Co said on Monday a small trial of its experimental Alzheimer's drug found that it slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
Saturday’s deal by
Alexion Pharmaceuticals brings a franchise in rare immune disorders to Astra, while also bringing to a close a campaign by discontented Alexion stockholders to get the company sold.
AstraZeneca’s $39 billion payment in cash and stock was valued at $175 per share of Alexion, and the stock of Alexion (ticker: ALXN) jumped 30% on Monday’s open, to $157. Shares of AstraZeneca (AZN) slipped 6.3%, however, to $50.88.
The deal will just about use up AstraZeneca’s capital available for deal-making. Investors have mixed feelings.
Although Alexion enjoys strong cash flow from treatments for disorders in a part of the immune system known as the complement, SVB Leerink analyst Andrew Berens raised concerns about expiring patents on Alexion’s big-selling drug Soliris. He said, though, that before that becomes a problem, the addition of Alexion could nearly double AstraZeneca’s cash flow in the next five years.